About this Research Topic
Lung cancer is one of the primary causes of cancer-related mortality globally, with its microenvironment playing a crucial role in tumor progression and the development of therapeutic resistance. Over the years, pulmonary fibrosis, a chronic lung condition, has been intimately linked to the onset, progression, and prognosis of lung cancer. It significantly alters lung architecture, leads to compromised gas exchange and respiratory function, and modifies the tumor microenvironment, promoting the growth of lung cancer cells and their evasion from immune surveillance, thereby affecting the delivery and efficacy of chemotherapeutic agents. Furthermore, inflammation and fibrosis interact in a complex manner within the lung cancer context, collectively shaping the tumor microenvironment.
It is worth noting that the concept of individualized treatment has been widely put forward based on different stages of disease development and specific molecular markers. In addition, the field of drug development is also actively exploring new treatment methods, including targeted therapy and immunotherapy. The implementation of these strategies will bring great breakthroughs and progress in the treatment of lung cancer and pulmonary fibrosis. Immunotherapy, as an emerging treatment strategy for lung cancer, encounters unique challenges when administered to patients with concurrent pulmonary fibrosis. Nanotargeting therapeutic strategies, leveraging biomarkers associated with fibrosis, present new possibilities for the delivery of lung cancer drugs. To sum up, this study aims to deeply explore the interaction between lung cancer and pulmonary fibrosis, understand the molecular and cellular pathogenesis, put forward innovative treatment strategies, and provide new ideas and directions for drug development, so as to promote the therapeutic effect of lung cancer.
We welcome the submission of review articles and original research papers in this field. Potential topics include, but are not limited to the following:
● Lung Cancer Microenvironment: The Role of Fibrosis in Tumor Progression and Treatment Resistance
● Pulmonary Fibrosis in the Context of Lung Cancer: Pathogenic Links and Therapeutic Targets.
● Fibrosis as a Comorbidity in Lung Cancer: Impact on Prognosis and Treatment Outcomes.
● Inflammation, Fibrosis, and Lung Cancer: The Role of the Tumor Microenvironment.
● Immunotherapy in Lung Cancer and Co-occurring Pulmonary Fibrosis: Challenges and Opportunities.
● Nanotargeting in Lung Cancer: The Role of Fibrosis-Associated Biomarkers for Drug Delivery.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic
It is worth noting that the concept of individualized treatment has been widely put forward based on different stages of disease development and specific molecular markers. In addition, the field of drug development is also actively exploring new treatment methods, including targeted therapy and immunotherapy. The implementation of these strategies will bring great breakthroughs and progress in the treatment of lung cancer and pulmonary fibrosis. Immunotherapy, as an emerging treatment strategy for lung cancer, encounters unique challenges when administered to patients with concurrent pulmonary fibrosis. Nanotargeting therapeutic strategies, leveraging biomarkers associated with fibrosis, present new possibilities for the delivery of lung cancer drugs. To sum up, this study aims to deeply explore the interaction between lung cancer and pulmonary fibrosis, understand the molecular and cellular pathogenesis, put forward innovative treatment strategies, and provide new ideas and directions for drug development, so as to promote the therapeutic effect of lung cancer.
We welcome the submission of review articles and original research papers in this field. Potential topics include, but are not limited to the following:
● Lung Cancer Microenvironment: The Role of Fibrosis in Tumor Progression and Treatment Resistance
● Pulmonary Fibrosis in the Context of Lung Cancer: Pathogenic Links and Therapeutic Targets.
● Fibrosis as a Comorbidity in Lung Cancer: Impact on Prognosis and Treatment Outcomes.
● Inflammation, Fibrosis, and Lung Cancer: The Role of the Tumor Microenvironment.
● Immunotherapy in Lung Cancer and Co-occurring Pulmonary Fibrosis: Challenges and Opportunities.
● Nanotargeting in Lung Cancer: The Role of Fibrosis-Associated Biomarkers for Drug Delivery.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic
Keywords: lung cancer, pulmonary fibrosis, pathological mechanism, therapeutic strategy, drug development, microenvironment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
